Award
NIH Reporter #5R01AG065248-05
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months
Recipient
Cognition Therapeutics, Inc.
Award Amount
$16,494,670.00
Ceiling
$16,494,670.00
Awarded
August 25, 2026
Identifier
5R01AG065248-05
The project funds a Phase 2 clinical trial of CT1812, a candidate Alzheimer’s disease therapy, to assess safety and effects on cognition and disease-related biomarkers in early-stage patients.
Description
A randomized, double-blind, placebo-controlled Phase 2 trial evaluating the safety, tolerability, and efficacy of two doses of CT1812 in patients with early Alzheimer's disease over 18 months.